William Blair analyst Sami Corwin has maintained their bullish stance on KRYS stock, giving a Buy rating on September 9.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sami Corwin has given his Buy rating due to a combination of factors including the recent FDA approval of an updated label for Krystal Biotech’s Vyjuvek. The new label allows Vyjuvek to be prescribed to infants from birth and enables at-home administration, which is significant as the majority of DEB patients in the U.S. prefer home treatment.
This expansion is expected to increase the patient base and improve accessibility, aligning the U.S. label with the EU’s. Corwin believes that these changes, along with Vyjuvek’s potential to enhance patient quality of life and its broader market opportunities, underscore a promising revenue outlook. Furthermore, the current market valuation of Krystal Biotech does not fully account for Vyjuvek’s long-term revenue potential and upcoming clinical developments, reinforcing the Buy recommendation.
In another report released on September 9, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $164.00 price target.